Valuation : Aptevo Therapeutics Inc.

Market Cap 4.4M 3.79M 3.55M 3.24M 6.1M 418M 6.14M 42.12M 16.39M 212M 16.51M 16.15M 702M P/E 2026 *
-0.14x
P/E 2027 * -0.37x
Enterprise Value 4.4M 3.79M 3.55M 3.24M 6.1M 418M 6.14M 42.12M 16.39M 212M 16.51M 16.15M 702M EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
94.28%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 61 2026-03-31
Director of Finance/CFO 60 2023-03-02
Chief Tech/Sci/R&D Officer 59 2026-05-27
Director TitleAgeSince
Chairman 64 2026-03-31
Director/Board Member 61 2026-03-31
Director/Board Member 71 2016-07-31
Date Insider Type Main position Quantity % Market Cap. Importance
8/6/26 Exercice

Chief Technology Officer

1,432 0.1149%
8/6/26 Exercice

Director

800 0.0642%
8/6/26 Exercice

Chief Executive Officer

1,922 0.1542%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 4.26M
-1.66%-4.96%+49.84%+88.43% 69.54B
-2.19%+1.32%+44.54%+88.38% 64.97B
-0.08%+0.53%+35.80%+10.67% 26.51B
+2.77%-1.74%-16.16%+456.51% 25.89B
-0.46%-9.94%+0.98%-15.98% 25.64B
-9.71%-0.36%+245.87%+377.68% 20.22B
-1.58%+0.47%+29.35%-19.62% 19.98B
-2.05%-6.54%+0.58%+538.95% 15.69B
+0.35%+0.16%+46.96%+144.04% 13.49B
Average -1.41%-2.78%+48.64%+185.45% 28.19B
Weighted average by Cap. -1.58%-2.68%+46.52%+146.22%

Financials

2026 *2027 *
Net sales - -
Net income -26.82M -23.09M -21.68M -19.79M -37.18M -2.55B -37.44M -257M -99.95M -1.29B -101M -98.49M -4.28B -28.69M -24.7M -23.19M -21.17M -39.77M -2.73B -40.06M -275M -107M -1.38B -108M -105M -4.58B
Net Debt - -
Logo Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel bispecific immunotherapies for the treatment of cancer. The Company has two clinical candidates: Mipletamig and ALG.APV-527. Mipletamig is being evaluated in RAINIER, a two-part Phase 1b/2 trial for the treatment of frontline acute myeloid leukemia in combination with standard-of-care venetoclax + azacitidine. Mipletamig has received orphan drug designation for AML according to the Orphan Drug Act. ALG.APV-527, a bispecific conditional 4-1BB agonist, only active upon simultaneous binding to 4-1BB and 5T4, is being co-developed with Alligator Bioscience and is being evaluated in a Phase 1 clinical trial for the treatment of multiple solid tumor types likely to express 5T4. The Company has three pre-clinical candidates with different mechanisms of action designed to target a range of solid tumors. All pipeline candidates are created from two proprietary platforms, ADAPTIR and ADAPTIR-FLEX.
Employees
33
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
2.440USD
Average target price
25.50USD
Spread / Average Target
+945.08%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. APVO Stock